GLP-1R agonists (e.g., exendin-4 and liraglutide) reduce APP expression and processing in the brains of AD model mice through the activation of GLP-1R, decrease A protein production and plaque aggregation, and thus improve their spatial memory capacity ( 2.2 GLP-1R and tau protein hyperphosphorylation Hyperphosphorylated tau is a major component of intracellular neurofibrillary tangles (NFTs), which, together with amyloid plaques, are a distinguishing marker of AD (Figure 1)
The risk is not eating enough specifically, not eating enough protein
Next, compile your medical documentation
In the placebo group, only 0.7% reported it
For example, some patients with Medicare discovered their expensive GLP-1 therapy (for CV risk reduction) was denied without explanations, leading to legal and public policy debate ( [21] ) ( [65] )